Hodgkin lymphoma is a malignancy of lymphocytes. Approximately half of all cases are due to the Epstein-Barr virus (EBV) of which being HIV positive is also a risk factor.

Hodgkin lymphoma can be divided into two subtypes, classical and nodular lymphocyte-predominant Hodgkin lymphoma.
The majority of classical Hodgkin lymphoma is composed of a mixed inflammatory infiltrate composed of lymphocytes, eosinophils, fibroblasts, macrophages and plasma cells as opposed to the classical Reed-Sternberg cells. Nodular, lymphocyte-predominant Hodgkin lymphoma is a rare entity and accounts for less than 5% of cases.

It is characterized by the presence of lymphocyte-predominant cells which expressed CD20, CD79a, and EMA but not CD30 or CD15 which is expressed in the classical type. Overall, Hodgkin lymphoma has a high cure rate and overall survival. However, exposure to radiation and chemotherapy in those patients diagnosed at a young age increases their risk of other malignancies later in life.

View Lymphoma Overview Page

Hodgkin Lymphoma

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Hodgkin Lymphoma

Hodgkin lymphoma is a malignancy of lymphocytes. Approximately half of all cases are due to the Epstein-Barr virus (EBV) of which being HIV positive is also a risk factor.

Hodgkin lymphoma can be divided into two subtypes, classical and nodular lymphocyte-predominant Hodgkin lymphoma.
The majority of classical Hodgkin lymphoma is composed of a mixed inflammatory infiltrate composed of lymphocytes, eosinophils, fibroblasts, macrophages and plasma cells as opposed to the classical Reed-Sternberg cells. Nodular, lymphocyte-predominant Hodgkin lymphoma is a rare entity and accounts for less than 5% of cases.

It is characterized by the presence of lymphocyte-predominant cells which expressed CD20, CD79a, and EMA but not CD30 or CD15 which is expressed in the classical type. Overall, Hodgkin lymphoma has a high cure rate and overall survival. However, exposure to radiation and chemotherapy in those patients diagnosed at a young age increases their risk of other malignancies later in life.

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter